China’s NMPA suspends import, sale of Dr. Reddy’s ADHD drug; shares slump 2.26%
The National Medical Products Administration (NMPA) of China has suspended import, sale, and use of drugmaker Dr. Reddy’s Laboratories’ Atomoxetine Hydrochloride capsules effective August 30, 2024. The action followed a remote inspection of the company’s formulations manufacturing facility (FTO-3 in Bachupally, Hyderabad) for Atomoxetine Hydrochloride capsules recently by NMPA. It “concluded the production quality management…
Read More “China’s NMPA suspends import, sale of Dr. Reddy’s ADHD drug; shares slump 2.26% ” »